The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association

  • Z. S. Khachaturian
  • T. S. Radebaugh
Part of the Advances in Alzheimer Disease Therapy book series (AADT)


Current efforts toward developing treatments to delay the symptoms of AD will not be adequate to overcome the demographic forces which are increasing the total number of affected individuals. The prevalence of AD increases nearly exponentially with age, that is, the percentage of the population affected doubles every decade beyond age 65. By delaying the onset of disabling symptoms for all age groups by five to ten years, it would be possible to reduce the number of people affected by half and cut the cost of care significantly.


Drug Discovery Program Commercial Partner Joint Research Venture Demographic Force Research Funding Organization 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Boston 1997

Authors and Affiliations

  • Z. S. Khachaturian
  • T. S. Radebaugh

There are no affiliations available

Personalised recommendations